Harrow Health acquires US rights to four eye drops
Click Here to Manage Email Alerts
Harrow Health acquired the United States commercialization rights to four ophthalmic drops from Novartis, according to a press release.
The acquisition includes the 1% and 0.5% formulations of Iopidine (apraclonidine hydrochloride), Maxitrol 0.1% (neomycin and polymyxin B sulfate and dexamethasone) and Moxeza 0.5% (moxifloxacin hydrochloride).
The company plans to sell, market and distribute the products through subsidiary, ImprimisRx. Novartis will retain commercial rights outside of the U.S.
“These acquisitions, along with previously announced transactions for AMP-100, MAQ-100, and the expansion of our relationship to sell and market Dexycu, are consistent with our strategic mission to leverage the ImprimisRx commercial platform by adding high-value FDAapproved products into our family of ophthalmic pharmaceutical products,” Harrow Health CEO, Mark L. Baum, said in the release. “We are excited about the benefits these newest products provide our more than 10,000 customers, and we expect ImprimisRx’s commercial and distribution platform to be a tremendous advantage in the lifecycle management of these clinically valuable medicines.”
Perspective
Back to Top
Imprimis continues to expand its offering to clinicians who provide solutions through both FDA-approved and compounded products. These four products are complements to its existing portfolio and align with its focus in ophthalmic surgery. It also provides an option for those doctors who prefer approved products for patients who want to use their insurance benefits. These products can all be distributed by the ImprimisRx pharmacy and do not require a specialty pharmacy.
These newest products that Imprimis acquired U.S. commercialization rights to are generally well known and highly utilized by clinicians. Maxitrol is a steroid/antibiotic combination eye drop that is commonly used after cataract and LASIK surgery. It also is commonly used for nonspecific inflammatory conditions of the ocular surface and adnexa.
Iopidine 1% is the only eye drop indicated to control IOP spikes associated with laser trabeculoplasty, iridotomy and YAG capsulotomy procedures. Iopidine 0.5% is indicated to delay ocular surgery as a short-term adjunctive therapy in patients already on maximally tolerated glaucoma therapies.
Moxeza is a topical fluoroquinolone anti-infective eye drop used to treat bacterial conjunctivitis. It provides a superior dosing regimen (twice daily) with broad microbial coverage.
Along with its other offerings from its 503B outsourcing facility and PCAB-accredited 503A patient-specific pharmacy, Imprimis has truly become an invaluable partner to eye care practitioners.
Collapse
Read more about
Click Here to Manage Email Alerts